CYSTADROPS Drug Patent Profile

« Back to Dashboard

Which patents cover Cystadrops, and when can generic versions of Cystadrops launch?

Cystadrops is a drug marketed by Recordati Rare and is included in one NDA.

The generic ingredient in CYSTADROPS is cysteamine hydrochloride. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the cysteamine hydrochloride profile page.

Summary for CYSTADROPS

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	119
Clinical Trials:	1
Patent Applications:	2,901
Drug Prices:	Drug price information for CYSTADROPS
What excipients (inactive ingredients) are in CYSTADROPS?	CYSTADROPS excipients list
DailyMed Link:	CYSTADROPS at DailyMed

See drug prices for CYSTADROPS

Recent Clinical Trials for CYSTADROPS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Recordati Rare Diseases	Phase 3

See all CYSTADROPS clinical trials

Pharmacology for CYSTADROPS

Drug Class	Cystine Depleting Agent
Mechanism of Action	Cystine Disulfide Reduction

US Patents and Regulatory Information for CYSTADROPS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Recordati Rare	CYSTADROPS	cysteamine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	211302-001	Aug 19, 2020		RX	Yes	Yes

Cystadrops Market Dynamics, Financial Trajectory, Patent Protection and Generic Risk

Last updated: September 26, 2026

Cystadrops is a cysteamine hydrochloride ophthalmic solution for corneal cystinosis, a rare complication of nephropathic cystinosis. Recordati markets the product through its rare-disease business after acquiring the product’s commercial rights from Leadiant Biosciences. The U.S. product received FDA approval in August 2018 with orphan-drug designation.[1]

Cystadrops has a narrow but durable market. Demand is driven by lifelong treatment, high disease severity, limited alternatives and the small number of diagnosed patients. Its commercial risks are concentrated in orphan-drug exclusivity, reimbursement, patient identification, competing cysteamine products and the timing of any abbreviated new drug application.

What is Cystadrops and who markets it?

Cystadrops contains cysteamine hydrochloride at a concentration of 0.37%. It is indicated for the treatment of corneal cystine crystal deposits in adults and children with cystinosis.[1]

Item	Cystadrops
Active ingredient	Cysteamine hydrochloride
Strength	0.37% ophthalmic solution
Dosage form	Topical eye drops
FDA approval	August 22, 2018
FDA application	NDA 210301
Therapeutic area	Rare ophthalmic disease and cystinosis
U.S. sponsor or marketer	Recordati Rare Diseases Inc.
Orphan designation	Yes
Administration	One drop in each eye four to seven times daily, depending on clinical response and labeling
Storage constraint	Refrigeration before opening; limited in-use period after opening

The product is supplied in small multi-dose bottles. The label instructs patients to discard each bottle after the specified in-use period, which increases monthly bottle utilization and raises the economic importance of packaging, distribution and adherence management.[1]

How large is the Cystadrops market?

The addressable market is small in patient count but high in value per treated patient. Nephropathic cystinosis is estimated to affect approximately one in 100,000 to 200,000 live births, with prevalence varying by geography and founder population.[2]

Corneal cystine accumulation develops in most untreated patients and can cause photophobia, ocular discomfort and progressive visual impairment. The treatment population therefore includes patients who may already receive systemic cysteamine but require a separate ophthalmic product.

The commercial market is shaped by four factors:

1. The patient pool is limited to individuals with cystinosis, particularly those with corneal involvement.
2. Treatment is chronic and generally continues for life.
3. Diagnosis and access to metabolic, renal and ophthalmic specialists are uneven.
4. Cystadrops competes with older cysteamine ophthalmic products and compounded preparations.

The total addressable population is therefore unlikely to support mass-market revenue. The product can still produce substantial revenue because orphan-disease pricing is based on high lifetime clinical need, specialist distribution and low competitive density.

What is Cystadrops’ financial trajectory?

Recordati does not generally report Cystadrops revenue as a separate line item in its consolidated financial statements. The company reports broader business segments and product groupings, including rare diseases. This prevents a precise public calculation of annual Cystadrops sales, gross margin or product-level growth.[3]

Recordati’s financial profile provides the relevant context:

Financial driver	Effect on Cystadrops
Chronic use	Supports recurring revenue and reduces dependence on new diagnoses
Orphan pricing	Increases revenue per treated patient
Small population	Limits absolute market size
Specialist distribution	Raises channel complexity but supports patient retention
International rights	Expands revenue beyond the U.S.
Reimbursement controls	Creates pressure on net price and patient access
Product concentration	Makes sales sensitive to a small number of patients and payers

The most likely financial trajectory is steady, specialty-pharmaceutical growth rather than rapid volume expansion. Revenue can increase through diagnosis rates, geographic expansion, improved persistence and conversion from older cysteamine products. Unit growth is structurally constrained by disease prevalence.

Recordati’s rare-disease portfolio also reduces the importance of any single product to group-level revenue. Cystadrops contributes to the portfolio’s recurring cash flow, but it is unlikely to be a primary driver of Recordati’s consolidated valuation without a material increase in diagnosed patients or pricing.

When did Cystadrops lose FDA orphan-drug exclusivity?

Cystadrops received FDA approval on August 22, 2018. FDA orphan-drug exclusivity generally lasts seven years from approval, placing the principal U.S. exclusivity date on August 22, 2025, subject to statutory exceptions and the precise scope of the protected indication.[1][4]

Orphan-drug exclusivity does not prevent every competing product from entering the market. It blocks FDA approval of the same drug for the same orphan indication during the exclusivity period, unless the sponsor cannot reliably supply the market or the competitor demonstrates clinical superiority.[4]

After the orphan period, entry risk depends on patents, FDA approval standards, formulation similarity and commercial economics. The end of orphan exclusivity does not automatically create generic competition.

What patents protect Cystadrops?

Cystadrops may be protected by a combination of formulation, manufacturing, use and regulatory exclusivity rights. The commercially important protection categories are:

Formulation protection

Cystadrops is an ophthalmic cysteamine formulation designed to improve stability, tolerability and duration of use compared with older cysteamine eye drops. These technical attributes can support formulation patent claims and create development barriers for competing products.

Method-of-use protection

Potential method-of-use claims may cover treatment of corneal cystine deposits in patients with cystinosis, dosing frequency, treatment duration or use in defined patient populations. The practical value of such claims depends on whether the claims are listed in the FDA Orange Book and whether a generic applicant must address them.

Manufacturing and stability protection

Cysteamine is chemically reactive and can present stability and oxidation challenges. Manufacturing controls, container closure systems, preservative performance, in-use stability and cold-chain procedures can create non-patent barriers even when patent protection is limited.

Current commercial analysis should distinguish between issued patents, pending applications, FDA Orange Book listings, regulatory exclusivity and trade secrets. A patent expiration date alone does not establish immediate generic entry.

What is the Orange Book status of Cystadrops?

The FDA Orange Book is the primary source for determining whether Cystadrops has listed patents that an ANDA applicant must address. The relevant listing analysis includes:

• NDA 210301;
• listed patents, if any;
• patent expiration dates;
• pediatric exclusivity, if applicable;
• labeling protection;
• the scope of any method-of-use claims.

FDA regulatory exclusivity and Orange Book patent listings are separate systems. A product can lose orphan exclusivity while retaining enforceable patents. Conversely, a listed patent may expire without producing a commercially viable generic challenge.

For Cystadrops, regulatory exclusivity was the clearest publicly identifiable early barrier. The post-2025 risk profile depends more heavily on the current Orange Book record, patent validity, formulation complexity and the willingness of generic manufacturers to invest in a very small ophthalmic market.[4]

Which companies challenge Cystadrops and what litigation affects it?

The principal competitive threat is not necessarily a direct patent lawsuit. It is the development of an alternative cysteamine ophthalmic product through the ANDA pathway or a competing branded orphan product.

Public FDA materials identify Cystaran as an earlier cysteamine ophthalmic treatment for corneal cystinosis. Cystaran contains cysteamine hydrochloride and was approved before Cystadrops.[5] The two products compete for the same clinical need but differ in formulation, concentration, storage, handling and administration requirements.

The cited FDA and Recordati materials do not establish a major publicly reported Hatch-Waxman settlement involving Cystadrops. No settlement date, authorized generic agreement or licensed generic launch should be assumed without a current court docket, FDA filing or company disclosure.

How does Cystadrops compare with Cystaran?

Attribute	Cystadrops	Cystaran
Active ingredient	Cysteamine hydrochloride	Cysteamine hydrochloride
Primary use	Corneal cystine crystals in cystinosis	Corneal cystine crystals in cystinosis
FDA approval	2018	2012
Formulation positioning	Stabilized ophthalmic solution	Earlier cysteamine ophthalmic product
Commercial role	Newer branded orphan product	Earlier branded product
Competitive risk	Generic or reformulated cysteamine products	Cystadrops and other cysteamine alternatives
Key differentiation	Handling, stability and dosing convenience	Established clinical use and earlier approval

Cystadrops’ commercial advantage depends on whether physicians and patients value its handling and dosing profile enough to offset payer restrictions or price differences. A competitor with equivalent clinical performance and a lower net price could pressure access even without a conventional generic launch.

What generic entry risks exist for Cystadrops?

Generic entry is technically possible because Cystadrops is a solution rather than a complex biologic. The principal barriers are commercial and regulatory:

• Small patient population limits the return on development investment.
• Ophthalmic products require precise quality, sterility and container-closure controls.
• Cysteamine stability can complicate formulation matching.
• The generic must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway.
• Labeling and method-of-use patents may require Paragraph IV certification.
• Specialist distribution and payer contracting can make market penetration slow.
• Existing Cystaran availability may reduce the economic incentive for another entrant.

A Paragraph IV filing would be the most visible signal of near-term generic risk. It could trigger patent litigation within 45 days of notice if the NDA holder or patent owner sues under the Hatch-Waxman framework.[6] Without a confirmed Paragraph IV filing, the probability of imminent entry cannot be inferred from orphan exclusivity expiration alone.

What manufacturing and geographic barriers affect Cystadrops?

Cystadrops’ manufacturing barriers include aseptic ophthalmic production, stability control, packaging, refrigerated distribution and compliance with ophthalmic quality standards. These barriers are manageable for established generic manufacturers but can deter smaller companies.

Geographic growth depends on regulatory approvals and reimbursement in each market. Recordati’s international rare-disease infrastructure supports distribution across Europe and other territories, but market access can differ substantially by country. Pricing, health technology assessment requirements, hospital procurement and national reimbursement policies influence the net revenue contribution outside the United States.[3]

The product’s geographic opportunity is therefore broader than its U.S. orphan market, but expansion remains dependent on country-level reimbursement and diagnosis rates.

How strong is the Cystadrops patent estate?

Cystadrops has a commercially defensible position based on orphan-disease economics, chronic use, specialist prescribing and formulation know-how. Its patent strength is harder to assess without relying on a current, verified patent-family review and Orange Book record.

The estate should be rated in three layers:

Protection layer	Assessment
Regulatory exclusivity	Strong during the seven-year orphan period; materially weaker after August 2025
Formulation and manufacturing	Potentially meaningful if claims cover stability, concentration, packaging or production
Market position	Durable because of rarity and specialist prescribing, but vulnerable to lower-priced cysteamine alternatives

The strongest commercial defense is likely the combination of patient loyalty, physician familiarity, reimbursement infrastructure and formulation performance. Patent protection alone may not prevent competition after regulatory exclusivity ends.

What are the main revenue scenarios for Cystadrops?

Base case

Sales remain stable or grow modestly as the company retains existing patients, expands diagnosis and maintains reimbursement. This is the most consistent scenario with a small chronic orphan market.

Downside case

Net price declines after orphan exclusivity, payers prefer Cystaran or compounded cysteamine, and a generic entrant captures a portion of treated patients. Revenue would fall before significant unit growth can offset the decline.

Upside case

Recordati increases diagnosis, improves international access, converts patients from older formulations and preserves premium reimbursement through demonstrated handling or adherence advantages.

The central financial variable is treated-patient count multiplied by annual net price. Because Recordati does not separately disclose Cystadrops sales, investors should monitor rare-disease segment growth, product commentary, reimbursement changes, regulatory filings and signs of generic development rather than rely on a standalone company-reported revenue series.

Key Takeaways

• Cystadrops is a chronic orphan ophthalmic treatment for corneal cystinosis.
• FDA approval occurred on August 22, 2018.
• The seven-year U.S. orphan exclusivity period generally ended on August 22, 2025.
• Recordati does not publicly disclose a standalone Cystadrops revenue figure in its consolidated reporting.
• The market has low patient volume but high recurring revenue per treated patient.
• Cystaran is the main established cysteamine ophthalmic comparator.
• Generic risk depends on Orange Book patents, formulation complexity, Paragraph IV activity and commercial incentives.
• No major publicly documented Cystadrops Hatch-Waxman settlement is established by the cited sources.
• Long-term revenue is more likely to be stable or moderately declining than to show mass-market expansion.
• The product’s strongest defenses are chronic treatment, specialist use, formulation know-how and distribution infrastructure.

FAQs

What disease does Cystadrops treat?

Cystadrops treats corneal cystine crystal accumulation associated with cystinosis, a rare inherited lysosomal storage disorder.

Is Cystadrops a biologic?

No. Cystadrops is a small-molecule cysteamine hydrochloride ophthalmic solution.

Can patients substitute Cystaran for Cystadrops?

Substitution requires clinical judgment. The products contain cysteamine but have different formulations, labeling, handling requirements and commercial positioning.

Does the end of orphan exclusivity guarantee a Cystadrops generic?

No. A generic applicant still must obtain FDA approval and address applicable patents, formulation requirements, sterility standards and commercial economics.

Why can Cystadrops generate meaningful revenue despite a small market?

The product is used chronically in a rare disease, and orphan-drug pricing, specialist distribution and lifetime treatment duration can produce substantial revenue per treated patient.

References

1. U.S. Food and Drug Administration. (2018). Cystadrops prescribing information. FDA.

2. National Organization for Rare Disorders. (n.d.). Cystinosis. NORD.

3. Recordati S.p.A. (2023). Annual report 2023. Recordati.

4. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. FDA.

5. U.S. Food and Drug Administration. (2012). Cystaran prescribing information. FDA.

6. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. FDA.